Jump to content

User:Adam Harangozó (NIHR WiR)/sandbox

From Wikipedia, the free encyclopedia
This page is about ambulatory cancer care in the United Kingdom. For ambulatory care in general, see Ambulatory care.

Ambulatory cancer treatment or ambulatory cancer care refers to the hospital-led coordination and delivery of cancer treatment on an outpatient basis that would traditionally require an inpatient stay. Coordinated by a hospital team and with daily visits to a treatment centre, ambulatory cancer care patients stay at home or in accommodation close to the hospital overnight.

Ambulatory cancer care is a safe alternative to inpatient cancer care. By enabling people undergoing treatment for cancer to continue aspects of their everyday lives, it can support people's autonomy and contribute to a more positive experience.

Definition

[edit]

In general terms, ambulatory care is medical care provided on an outpatient basis. Ambulatory care encompasses a broad scope of clinical specialties and treatments.[1]

Ambulatory cancer are typically refers to the provision of systemic anti-cancer therapies on an outpatient basis that would have traditionally required an inpatient stay.[2]

Ambulatory cancer care facilitates the delivery of intravenous therapy and chemotherapy when the cancer protocol involves a continuous or intermittent infusion over several days.[3][2] Some chemotherapy regimens can be given entirely on an ambulatory basis. Other treatments, for example an allogeneic haematopoietic (stem cell) transplant, can have a pre-determined time when patients are admitted to an inpatient ward.[3]

In ambulatory cancer care, patients can stay in a residential setting overnight, returning to an ambulatory unit each day for clinical review, infusion change or treatment. Overnight accommodation could be their usual home,[4][5][6] a hospital hotel/apartment,[7] or a commercial hotel.[8] When determining suitability for ambulatory treatment, patients need to be clinically stable and able to engage in aspects of self-monitoring, for example recording their body temperature, measuring their urine output and/or keeping a fluid balance chart.[3] Although not a requirement, most patients choose to be accompanied by a family member or friend overnight. Although ambulatory patients receive their daily clinical review and/or treatment in a day care or outpatient setting they are, for all intents and purposes, considered inpatients by their medical and nursing team and require vigilant, pre-emptive care.[9]

History

[edit]

Ambulatory cancer care was conceived in the US in the 1980s and reflected a shift towards more individualised, person-centred care. Foremost, however, it mirrored increasing rates of cancer and associated healthcare demand which had begun to challenge inpatient bed capacity, and delivery of on-time cancer treatment.[2]

Technological progress helped pave the way for ambulatory cancer treatment internationally. The development of portable infusion pumps, haematopoietic growth factors and better antiemetics (anti-nausea medication) contributed to the feasibility of ambulatory care of people with cancer.[2][10] By the 1990s in the US, significant progress had been made in transitioning inpatient cancer treatment to ambulatory pathways.[11]

In the UK, the development of ambulatory cancer care was influenced by the concepts of self-care, where people with illness are seen as active partners. Whereas in the US, ambulatory care's development was driven by cost savings and fiscal benefits, it was the opportunity to increase NHS cancer treatment capacity together with the potential for enhanced patient experience that provided the impetus for ambulatory cancer care in the UK.[2][4] Here, the first NHS ambulatory care service was modelled on USA cancer services, especially the practice at Memorial Sloan Kettering Cancer Center (MSKCC) in New York.[2] A field visit to MSKCC by a team from University College London Hospitals NHS Foundation Trust in the early 2000s, led to their initial piloting of ambulatory cancer care in 2003 with the administration of high-dose methotrexate. The team also ran a pilot exploring adult patients’ experience of receiving a BEAM (carmustine, etoposide, cytarabine, melphalan) haematopoietic stem cell transplant on an ambulatory basis at UCLH.[12] Between 2005 and 2011, an additional 1443 adults with cancer were treated via ambulatory care.[8] Adult ambulatory care is now a mainstay of the UCLH NHS Foundation Trust's cancer services.[13]

Other NHS cancer treatment centres have since developed adult ambulatory cancer services, notably at the Leeds Teaching Hospitals NHS Trust,[14] the Sheffield Teaching Hospitals NHS Foundation Trust and The Christie NHS Foundation Trust.[15] In young people's cancer services, the first NHS Teenage and Young Adult Ambulatory Care Service was established in 2012 at UCLH, to coincide with the opening of its UCH Macmillan Cancer Centre.[16][17]

With growing interest and an emerging evidence base reporting how the pathway positively contributes to young people's experiences of cancer treatment,[7] in autumn 2022 a national Special Interest Group hosted by the Children's Cancer and Leukaemia Group (CCLG) in collaboration with Teenage and Young Adult Cancer (TYAC) was formed, bringing together healthcare professionals committed to the development of children and young people's ambulatory cancer care in across the UK.[18]

Nursing in ambulatory cancer care

[edit]

Ambulatory cancer care is a nurse-led service. The nursing team based in ambulatory care is integral to the development and running of the services. Nursing teams within ambulatory cancer care are responsible for patient clinical care, patient education as well as service management and development. Experienced nurses lead in assessing patient suitability to ambulate, closely monitor symptoms and toxicities from treatments, and are the patient's main point of contact throughout their stay.[19]

As many aspects of monitoring are managed by a patient in ambulatory cancer care (often together with their carer), education is delivered by nurses to ensure safe and effective care.[3] Education typically covers the treatment protocol, supportive care, self-monitoring, potential toxicities to be aware of, medication administration, management and troubleshooting of Computerised Ambulatory Delivery Devices (CADD pumps). Following education, both patient and nurse sign a contract agreeing to the conditions of the ambulatory stay.[3]

Local operational processes and procedures vary between centres, but all need to be robust and clear. Senior ambulatory cancer care nurses draw on their knowledge and expertise, playing a key role in service development and care pathway improvement.

Safety

[edit]

The safety of ambulatory cancer care has been demonstrated within different international settings from the perspective of not having increased mortality, infection or toxicities, building confidence in the safety and feasibility of the service.[20][21][8][22][23] Responsibility for safety is seen as shared in ambulatory cancer care between the patient and the healthcare team, together with an accompanying family member or friend.[7]

A clinical safety net is now understood to be key in assuring both clinical safety and confidence in ambulatory cancer care. This includes a 24-hour telephone advice line; staying in proximity to the hospital; ensuring access to the full complement of the multi-disciplinary team; and appropriate patient education to confidently engage in self-monitoring and self-surveillance.

Patient experience

[edit]

Ambulatory cancer care is widely understood to contribute positively to people's experiences of cancer treatment.[4][24][25] This derives from people of all ages being able to make and exercise choices about how time is passed;[7][16] experience freedom from the hospital environment;[3] feel empowered and independent.[4][7][24]

Within young people's services, ambulatory cancer treatment supports the delivery of age-appropriate care.[26] This is enabled by a greater opportunity to offer individualised, person-centred care through ambulatory cancer treatment, in comparison with inpatient care.[7] Ambulatory cancer care helps retain aspects of life that are important to young people; anchoring them in aspects of their usual life and relationships.[2][7]

References

[edit]
  1. ^ Tlapa, Diego; Zepeda-Lugo, Carlos A.; Tortorella, Guilherme L.; Baez-Lopez, Yolanda A.; Limon-Romero, Jorge; Alvarado-Iniesta, Alejandro; Rodriguez-Borbon, Manuel I. (6 February 2020). "Effects of Lean Healthcare on Patient Flow: A Systematic Review". Value in Health. 23 (2): 260–273. doi:10.1016/j.jval.2019.11.002. PMID 32113632.
  2. ^ a b c d e f g Finch, Alison; Cooper, Silvie; Raine, Rosalind; Taylor, Rachel M.; Gibson, Faith (2023-06-20). Qian, Liren (ed.). "The Development of Ambulatory Cancer Care in the UK: A Scoping Review of the Literature". European Journal of Cancer Care. 2023: 1–18. doi:10.1155/2023/4589362. ISSN 1365-2354.
  3. ^ a b c d e f Ingram, Bethan (2017-02-23). "Ambulatory care for haematology and oncology patients". British Journal of Nursing. 26 (4): S12–S14. doi:10.12968/bjon.2017.26.4.S12. ISSN 0966-0461. PMID 28230429.
  4. ^ a b c d Comerford, Diana; Shah, Raakhee (2018-09-20). "Ambulatory approach to cancer care. Part 1: the patient experience". British Journal of Nursing. 27 (17): S4–S12. doi:10.12968/bjon.2018.27.17.S4. ISSN 0966-0461. PMID 30235032. S2CID 52306687.
  5. ^ Mahadeo, Kris M.; Santizo, Ruth; Baker, Lindsay; Curry, Joan O'Hanlon; Gorlick, Richard; Levy, Adam S. (2010-12-15). "Ambulatory high-dose methotrexate administration among pediatric osteosarcoma patients in an urban, underserved setting is feasible, safe, and cost-effective". Pediatric Blood & Cancer. 55 (7): 1296–1299. doi:10.1002/pbc.22772. ISSN 1545-5009. PMID 20949591.
  6. ^ Ranney, Lori; Hooke, Mary C.; Robbins, Kathryn (2020-02-26). "Letting Kids Be Kids: A Quality Improvement Project to Deliver Supportive Care at Home After High-Dose Methotrexate in Pediatric Patients With Acute Lymphoblastic Leukemia". Journal of Pediatric Oncology Nursing. 37 (3): 212–220. doi:10.1177/1043454220907549. ISSN 1043-4542. PMC 7492745. PMID 32102635.
  7. ^ a b c d e f g Finch, Alison C (2023-03-28). Experiences of teenage and young adult ambulatory cancer care: Community-Based Participatory Research to inform service provision (Doctoral thesis). UCL (University College London).
  8. ^ a b c Sive, Jonathan; Ardeshna, Kirit M.; Cheesman, Simon; le Grange, Franel; Morris, Stephen; Nicholas, Claire; Peggs, Karl; Statham, Paula; Goldstone, Anthony H. (13 June 2012). "Hotel-based ambulatory care for complex cancer patients: a review of the University College London Hospital experience". Leukemia & Lymphoma. 53 (12): 2397–2404. doi:10.3109/10428194.2012.694430. ISSN 1042-8194. PMID 22591143. S2CID 21469606.
  9. ^ Mcmonagle, Lisa-Marie (2018), Olsen, Pia Riis; Smith, Sam (eds.), "Nurse-Led Ambulatory Care", Nursing Adolescents and Young Adults with Cancer, Cham: Springer International Publishing, pp. 199–215, doi:10.1007/978-3-319-73555-9_12, ISBN 978-3-319-73554-2, retrieved 2023-09-28
  10. ^ Do, Tiffanie Thy; Yeh, James Jen-Chi (2021-05-20). "Reducing hospitalizations: Implementation of CADD pumps in infusion clinic at a Los Angeles safety net hospital". Journal of Clinical Oncology. 39 (15_suppl): e18648. doi:10.1200/JCO.2021.39.15_suppl.e18648. ISSN 0732-183X. S2CID 236341073.
  11. ^ Schulmeister, Lisa (May 1991). "Establishing a cancer patient education system for ambulatory patients". Seminars in Oncology Nursing. 7 (2): 118–124. doi:10.1016/0749-2081(91)90090-C. PMID 1715598.
  12. ^ Statham, P (2005). The patient's experience of receiving a BEAM haematopoietic stem cell transplant based within the ambulatory setting; an interpretive phenomenological inquiry (Masters Dissertation thesis). London South Bank University.
  13. ^ "Adult ambulatory care cancer service". University College London Hospitals NHS Foundation Trust. Retrieved 2023-09-27.
  14. ^ "Ambulatory care". Leeds Teaching Hospitals NHS Trust. Retrieved 2023-09-27.
  15. ^ "Ambulatory care". The Christie NHS Foundation Trust. Retrieved 2023-09-27.
  16. ^ a b Newton, Caroline; Ingram, Bethan (4 March 2014). "Ambulatory chemotherapy for teenagers and young adults". British Journal of Nursing. 23 (Sup2): S36–S42. doi:10.12968/bjon.2014.23.Sup2.S36. ISSN 0966-0461.
  17. ^ "Teenage and Young Adult Ambulatory Care Service". University College London Hospitals NHS Foundation Trust. Retrieved 2023-09-27.
  18. ^ "Ambulatory Care Special Interest Group Meeting". www.cclg.org.uk. Retrieved 2023-09-27.
  19. ^ Comerford, Diana; Shah, Raakhee (2019-02-28). "Ambulatory approach to cancer care. Part 2: the role of nurses and the multidisciplinary team and safety". British Journal of Nursing. 28 (4): S20–S26. doi:10.12968/bjon.2019.28.4.S20. ISSN 0966-0461. PMID 30811233. S2CID 73487721.
  20. ^ Zelcer, Shayna; Kellick, Michael; Wexler, Leonard H.; Gorlick, Richard; Meyers, Paul A. (11 February 2008). "The Memorial Sloan Kettering Cancer Center experience with outpatient administration of high dose methotrexate with leucovorin rescue". Pediatric Blood & Cancer. 50 (6): 1176–1180. doi:10.1002/pbc.21419. ISSN 1545-5009. PMID 18266225. S2CID 21260825.
  21. ^ Bakhshi, Sameer; Singh, Preetpaul; Swaroop, Chetanya (October 2009). "Outpatient consolidation chemotherapy in pediatric acute myeloid leukemia: a retrospective analysis". Hematology. 14 (5): 255–260. doi:10.1179/102453309X446144. ISSN 1607-8454. PMID 19843379.
  22. ^ Villegas Rubio, Jose A.; Cacciavillano, Walter; Rose, Adriana; Zubizarreta, Pedro; Scopinaro, Marcelo (October 2017). "Ambulatory High-dose Methotrexate Administration in Pediatric Osteosarcoma Patients at a Single Institution in Argentina". Journal of Pediatric Hematology/Oncology. 39 (7): e349–e352. doi:10.1097/MPH.0000000000000922. ISSN 1077-4114. PMID 28937522. S2CID 11695613.
  23. ^ Fridthjof, Katrine S.; Kampmann, Peter; Dünweber, Anne; Gørløv, Jette S.; Nexø, Connie; Friis, Lone S.; Nørskov, Kristina H.; Welinder, Pernille C.; Moser, Claus; Kjeldsen, Lars; Møller, Tom (20 April 2018). "Systematic patient involvement for homebased outpatient administration of complex chemotherapy in acute leukemia and lymphoma". British Journal of Haematology. 181 (5): 637–641. doi:10.1111/bjh.15249. ISSN 0007-1048. PMID 29676445.
  24. ^ a b Brown, Laura; Walker, Amber (2016). "Exploring Stakeholder's Perceptions of Teenage and Young Adult Cancer Ambulatory Care". Foundation of Nursing Studies. Retrieved 2023-12-23.
  25. ^ Nissim, Rinat; Rodin, Gary; Schimmer, Aaron; Minden, Mark; Rydall, Anne; Yuen, Dora; Mischitelle, Ashley; Fitzgerald, Peter; Lo, Christopher; Gagliese, Lucia; Zimmermann, Camilla (5 April 2014). "Finding new bearings: a qualitative study on the transition from inpatient to ambulatory care of patients with acute myeloid leukemia". Supportive Care in Cancer. 22 (9): 2435–2443. doi:10.1007/s00520-014-2230-3. ISSN 0941-4355. PMID 24705856. S2CID 34850627.
  26. ^ Lea, Sarah; Taylor, Rachel M.; Martins, Ana; Fern, Lorna A.; Whelan, Jeremy S.; Gibson, Faith (2018-10-24). "Conceptualizing age-appropriate care for teenagers and young adults with cancer: a qualitative mixed-methods study". Adolescent Health, Medicine and Therapeutics. 9: 149–166. doi:10.2147/AHMT.S182176. PMC 6207223. PMID 30498386.
[edit]
Retrieved from "https://en.wikipedia.org/w/index.php?title=User:Adam_Harangozó_(NIHR_WiR)/sandbox&oldid=1211211667"